CerenseSM has substantial potential to facilitate the development of many new drug products to treat CNS disorders including Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, stroke, brain tumors and infections, traumatic brain injury, anxiety, depression and schizophrenia.
CerenseSM is designed to substantially improve the development success of potential CNS medicines that normally exhibit poor permeation of the BBB. It overcomes the challenges of CNS drug delivery and assessment by bringing together the strengths of Genzyme Pharmaceuticals and Pharmidex.
